Merck's human papillomavirus vaccine has been approved for men in China, it said on Wednesday, providing the U.S. drugmaker a ...
EQS-AFR: Merck KGaA: Preliminary announcement of the publication of quarterly reports and quarterly/interim statements ...
If approved, Pfizer’s sasanlimab will distinguish itself from Merck’s blockbuster Keytruda as the first PD-1 inhibitor ...
Hosted on MSN1d
Truist Securities Downgrades Merck (MRK)Fintel reports that on January 8, 2025, Truist Securities downgraded their outlook for Merck (NYSE:MRK) from Buy to Hold.
Two late-stage studies published Wednesday in The Lancet show that Astra's Imfinzi and Merck's Keytruda delayed the progress ...
Doctors may change how they treat liver cancer after drugs from AstraZeneca Plc and Merck & Co. helped some patients, marking ...
China's WuXi Biologics said on Monday it will sell its vaccine facility in Ireland to U.S. drugmaker Merck & Co for about ...
Merck's Winrevair (sotatercept) gains UK approval for PAH treatment. Key trial results highlight significant exercise ...
We recently compiled a list of the 13 Best Pharma Dividend Stocks To Buy In 2024. In this article, we are going to take a ...
US drugmaker Merck & Co said on Wednesday its human papillomavirus (HPV) vaccine for men has been approved by China's medical products administration. The vaccine has been cleared to be used for males ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback